Evidence mapPaperPMID 34977908Full record

ArticleFree neuropathology2021

Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Jens Pahnke, Pablo Bascuñana, Mirjam Brackhan, Katja Stefan, Vigneshwaran Namasivayam, Radosveta Koldamova, Jingyun Wu, Luisa Möhle, Sven Marcel Stefan

Open access · greenAbstract read
In one paragraph

Article in Free neuropathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Alzheimer's disease in theFree neuropathology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. 25-Hydroxycholesterol in health and diseases.Journal of lipid research · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Frontiers in neuroscience · 2023
    Review
  12. Article
  13. Article
  14. Endothelin-1, over-expressed in SOD1Frontiers in cellular neuroscience · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Jens PahnkeDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Pablo BascuñanaDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Mirjam BrackhanDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Katja StefanDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Vigneshwaran NamasivayamDepartment of Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
Radosveta KoldamovaDepartment of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States of America.
Jingyun WuDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Luisa MöhleDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Sven Marcel StefanDepartment of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Bonn · DEUniversity of Pittsburgh · US

Funding

NIA NIH HHS R01 AG057565NIA NIH HHS R01 AG066198NIA NIH HHS RF1 AG056371
6 · The paper itself

Abstract

Adenosine-triphosphate-(ATP)-binding cassette (ABC) transport proteins are ubiquitously present membrane-bound efflux pumps that distribute endo- and xenobiotics across intra- and intercellular barriers. Discovered over 40 years ago, ABC transporters have been identified as key players in various human diseases, such as multidrug-resistant cancer and atherosclerosis, but also neurodegenerative diseases, such as Alzheimer's disease (AD). Most prominent and well-studied are ABCB1, ABCC1, and ABCG2, not only due to their contribution to the multidrug resistance (MDR) phenotype in cancer, but also due to their contribution to AD. However, our understanding of other ABC transporters is limited, and most of the 49 human ABC transporters have been largely neglected as potential targets for novel small-molecule drugs. This is especially true for the ABCA subfamily, which contains several members known to play a role in AD initiation and progression. This review provides up-to-date information on the proposed functional background and pathological role of ABCA transporters in AD. We also provide an overview of small-molecules shown to interact with ABCA transporters as well as potential

Indexed as

ABCA1 (ABC1)ABCA2ABCA5ABCA7ABCB1 (P-gp)ABCC1 (MRP1)ABCG2 (BCRP)ABC transporterActivationAlzheimer’s diseaseAmyloid-beta (Aβ / Abeta)Broad-spectrum modulatorDownregulationInductionInhibitionMultitarget inhibitor (PANABC)Pattern analysisPET Tracer (PETABC)PolypharmacologyRational drug design and development

Identifiers

PMID34977908
PMCPMC8717091
OpenAlexW4200316763

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.